Cori Ann Sherwin

First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma

Richard D. Kim, Debashis Sarker, Tim Meyer et al. · Cancer Discovery · 2019 · 239 citations · Full text

Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma

Megan Hatlen, Oleg Schmidt-Kittler, Cori Ann Sherwin et al. · Cancer Discovery · 2019 · 106 citations

RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations

Vivek Subbiah, Vaibhav Sahai, Dejan Maglic et al. · Cancer Discovery · 2023 · 103 citations · Full text

First-in-human study of highly selective FGFR2 inhibitor, RLY-4008, in patients with intrahepatic cholangiocarcinoma and other advanced solid tumors.

Alison M. Schram, Suneel D. Kamath, Anthony B. El-Khoueiry et al. · Journal of Clinical Oncology · 2021 · 14 citations

Pathology, Cholangiopathies, First-in-human Study +16

Abstract P02-02: First results of RLY-4008, a potent and highly selective FGFR2 inhibitor in a first-in-human study in patients with FGFR2-altered cholangiocarcinoma and multiple solid tumors

Lipika Goyal, Mitesh J. Borad, Vivek Subbiah et al. · Molecular Cancer Therapeutics · 2021 · 11 citations

Pathology, Pharmacotherapy, Selective Fgfr2 Inhibitor +17